biotech · Acute Myeloid Leukemia (AML) · Ovarian Cancer · STRO
SUTRO BIOPHARMA
SUTRO BIOPHARMA, INC.
SUTRO BIOPHARMA clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2003
- Employees
- 212
- Programs
- 10
- Drugs
- 21
- Patents
- 34
SUTRO BIOPHARMA projects
10 ClinicalTrials.gov programs sponsored by SUTRO BIOPHARMA.
SUTRO BIOPHARMA has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Luveltamab tazevibulin
SUTRO BIOPHARMA, INC.
Ovarian Cancer
1 trial -
Luveltamab tazevibulin
SUTRO BIOPHARMA, INC.
Lung Cancer
1 trial -
Luveltamab tazevibulin
SUTRO BIOPHARMA, INC.
Acute Myeloid Leukemia (AML)
1 trial -
REFRaME-P1
SUTRO BIOPHARMA, INC.
Acute Myeloid Leukemia (AML)
1 trial -
STRO-002
SUTRO BIOPHARMA, INC.
Neoplasm Malignant
1 trial -
STRO-002-GM3
SUTRO BIOPHARMA, INC.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)
1 trial -
STRO-001
SUTRO BIOPHARMA, INC.
B-cell Lymphoma
1 trial -
STRO-002
SUTRO BIOPHARMA, INC.
Ovarian Cancer
2 trials -
STRO-002-GM2
SUTRO BIOPHARMA, INC.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)
1 trial -
STRO-004
SUTRO BIOPHARMA, INC.
Head and Neck Squamous Cell Carcinoma HNSCC
1 trial
Frequently asked questions
How many clinical projects does SUTRO BIOPHARMA have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.